Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2021-04-09 AGM Information
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma: Notice to Annual General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled "Hansa Biopharma: Notice to Annual General Meeting" and details the date, procedures (advance voting due to Covid-19), proposed agenda items (including election of directors, approval of financial statements, remuneration, and incentive programs), and proposals from the Nomination Committee. This content is characteristic of the official notice and materials distributed to shareholders in preparation for an Annual General Meeting (AGM). While it contains elements that might appear in other filings (like remuneration proposals which could relate to DEF 14A, or financial statement approval which relates to 10-K/IR), the primary purpose and title clearly identify it as the AGM Notice/Materials. Therefore, the most appropriate classification is AGM-R.
2021-04-09 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder (Handelsbanken Fonder AB) in an issuer (Hansa Biopharma AB). It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and voting rights percentages, crossing a threshold (implied by the structure, as the resulting percentage is 5.23%). This type of filing, reporting changes in significant share ownership, corresponds directly to the Major Shareholding Notification category.
2021-04-08 English
Annual Report 2020
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2020' and contains comprehensive sections including a Chairman's letter, CEO statement, highlights, and references to financial and governance sections. It is a full-length corporate annual report, not an announcement or a summary. FY 2020
2021-04-08 English
Annual Report 2020
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2020' (Annual Report 2020) for Hansa Biopharma. It contains comprehensive sections including board comments, CEO statements, operational highlights, and strategic outlooks for the fiscal year 2020. It is clearly the full annual report document, not an announcement or a summary. FY 2020
2021-04-08 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding and voting rights for a specific instrument (Aktie SE0002148817) held by Handelsbanken Fonder AB in Hansa Biopharma AB. It explicitly shows the 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights crossing a threshold (5.005%). This structure is characteristic of a notification regarding changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-04-07 English
Hansa Biopharma enters preclinical research collaboration with argenx
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a "preclinical research collaboration agreement" between Hansa Biopharma and argenx. It details the nature of the collaboration, the technologies involved (imlifidase and efgartigimod), and includes standard boilerplate information about the companies and regulatory compliance ("This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation."). This type of announcement, detailing strategic business developments, partnerships, or research milestones, does not fit the specific definitions for 10-K, ER, IR, or DIV. It is a general corporate announcement regarding business strategy and development, which is best categorized as a Regulatory Filing (RNS) as it is a mandatory disclosure under EU regulations, or potentially a general announcement if a more specific category existed. Given the options, RNS serves as the best fit for a general, mandatory regulatory press release that isn't a core financial report or management change.
2021-03-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.